A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: * Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks; * Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.

Timeline

Start

2018-11-05

Primary completion

2019-05-14

Completion

2019-05-14

Drugs

Indications